Ken Griffin Sage Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 101,700 shares of SAGE stock, worth $582,741. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,700

Previous 13,100 676.34%

Holding current value

$582,741

Previous $245,000 350.61%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $3.25 Million - $5.5 Million	307,032 Added 191.24%	467,580 $5.08 Million
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $5.08 Million - $7.35 Million	-272,582 Reduced 62.93%	160,548 $3.01 Million
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $903,940 - $1.18 Million	52,862 Added 13.9%	433,130 $9.39 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $2.62 Million - $7.66 Million	156,442 Added 69.89%	380,268 $7.83 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $6.84 Million - $10 Million	168,302 Added 303.12%	223,826 $10.5 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $576,156 - $719,925	15,459 Added 38.58%	55,524 $2.33 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $3.96 Million - $5.37 Million	-123,031 Reduced 75.43%	40,065 $1.53 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $3.76 Million - $5.04 Million	116,406 Added 249.32%	163,096 $6.39 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $1.63 Million - $2.25 Million	-59,256 Reduced 55.93%	46,690 $1.51 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $30.5 Million - $45.3 Million	-991,899 Reduced 90.35%	105,946 $3.51 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $15.9 Million - $20.2 Million	427,855 Added 63.86%	1,097,845 $46.7 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $973,486 - $1.39 Million	24,180 Added 3.74%	669,990 $29.7 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $33.7 Million - $48.7 Million	614,791 Added 1981.98%	645,810 $36.7 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $33.1 Million - $45.3 Million	-468,425 Reduced 93.79%	31,019 $2.32 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $54.1 Million - $82.4 Million	-925,619 Reduced 64.95%	499,444 $43.2 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $13.9 Million - $21.1 Million	-338,550 Reduced 19.2%	1,425,063 $87.1 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $30 Million - $49.9 Million	1,155,806 Added 190.16%	1,763,613 $73.3 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $4.59 Million - $13.6 Million	175,585 Added 40.62%	607,807 $17.5 Million
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $20.6 Million - $52.9 Million	341,925 Added 378.67%	432,222 $31.2 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $11.8 Million - $16 Million	84,374 Added 1424.51%	90,297 $12.7 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $3.94 Million - $4.57 Million	-24,964 Reduced 80.82%	5,923 $1.08 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $50,918 - $93,280	570 Added 1.88%	30,887 $0
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $12.2 Million - $20.8 Million	-148,705 Reduced 83.07%	30,317 $2.9 Million
Q3 2018 Nov 13, 2018	BUY	$138.11 - $169.04 $21.2 Million - $26 Million	153,861 Added 611.51%	179,022 $0
Q2 2018 Aug 10, 2018	SELL	$140.36 - $175.76 $7.27 Million - $9.1 Million	-51,785 Reduced 67.3%	25,161 $0
Q1 2018 May 11, 2018	BUY	$152.15 - $192.33 $6.09 Million - $7.69 Million	39,995 Added 108.24%	76,946 $12.4 Million
Q4 2017 Feb 09, 2018	SELL	$60.72 - $167.34 $4.33 Million - $11.9 Million	-71,249 Reduced 65.85%	36,951 $6.09 Million
Q3 2017 Nov 09, 2017	BUY	$61.4 - $88.52 $6.64 Million - $9.58 Million	108,200	108,200 $6.74 Million

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

46.4M

Call Options Held

847K

Put Options Held

188K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account